Blinatumomab
- Generic Name
- Blinatumomab
- Brand Names
- Blincyto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 853426-35-4
- Unique Ingredient Identifier
- 4FR53SIF3A
- Background
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since b...
- Indication
Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to...
- Associated Conditions
- Precursor B-lymphoblastic leukaemia acute, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT03849651
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
- Conditions
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT03751709
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT03739814
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
- Conditions
- Interventions
- Drug: BortezomibDrug: BlinatumomabDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: DexamethasoneDrug: MyocetDrug: DoxorubicinDrug: 6-MercaptopurineDrug: EtoposideDrug: Fludarabine PhosphateDrug: PrednisoloneDrug: IfosfamideDrug: TioguaninDrug: PegaspargaseDrug: MethotrexateDrug: ErwinaseDrug: VincristineDrug: Vindesine
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Martin Schrappe
- Target Recruit Count
- 5000
- Registration Number
- NCT03643276
- Locations
- 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹S.O. Annunziata - A. O. Cosenza, Cosenza, Italy
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03628053
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Registration Number
- NCT03605589
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Marlise Luskin, MD
- Target Recruit Count
- 40
- Registration Number
- NCT03595917
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2023-07-13
- Target Recruit Count
- 71
- Registration Number
- NCT03541083
- Locations
- 🇳🇱
NL-Zwolle-ISALA, Zwolle, Netherlands
🇳🇱NL-Utrecht-UMCUTRECHT, Utrecht, Netherlands
🇳🇱NL-Enschede-MST, Enschede, Netherlands
PETHEMA-BLIN-01/PET069014 (BLIN-01)
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 11
- Registration Number
- NCT03523429
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 52
- Registration Number
- NCT03480438
- Locations
- 🇩🇪
Uniklinik RWTH Aachen, Aachen, Germany
🇩🇪University Hospital of Frankfurt (Main), Frankfurt (Main), Hessen, Germany
🇩🇪Charité - Campus Benjamin Franklin, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.